Skip to main content
Fig. 3 | Lipids in Health and Disease

Fig. 3

From: In silico profiling of nonsynonymous SNPs of fat mass and obesity-associated gene: possible impacts on the treatment of non-alcoholic fatty liver disease

Fig. 3

Drug-ligand interaction predicted for FTO and its mutants: (A) native FTO with capsaicin, (B) native FTO with resveratrol, (C) native FTO with rosmarinic acid, (D) R96P with capsaicin, (E) R96P with resveratrol, (F) R96P with rosmarinic acid, (G) G103D with capsaicin, (H) G103D with resveratrol, (I) G103D with rosmarinic acid, (J) Y295C with capsaicin, (K) Y295C with resveratrol, (L) Y295C with rosmarinic acid, (M) R316Q with capsaicin, (N) R316Q with resveratrol, (O) R316Q with rosmarinic acid, (P) R322Q with rosmarinic acid, (Q) R322Q with resveratrol, and (R) R322Q with rosmarinic acid

Back to article page